Nonalcoholic fatty liver disease (NAFLD) and its inflammatory and often progressive subtype
nonalcoholic steatohepatitis (NASH) are becoming the leading cause of liver-related …

Cardiovascular disease is a leading cause of death and reduced quality of life, proven by
the latest data of the Global Burden of Disease Study, and is only gaining in prevalence …

Abstract Systems medicine has a mechanism-based rather than a symptom-or organ-based
approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In …

Cirrhosis has become the major liver-related clinical endpoint in non-alcoholic
steatohepatitis (NASH). However, progression to cirrhosis is less predictable in NASH than …

Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental
factors and genetic determinants that cannot be completely replicated in animals …

Hepatocellular carcinoma (HCC) is an increasing burden on global public health and is
associated with enhanced lipogenesis, fatty acid uptake, and lipid metabolic …

Background & Aims Fibroblast activation protein (FAP) is expressed on activated fibroblast.
Its role in fibrosis and desmoplasia is controversial, and data on pharmacological FAP …

Chronic hepatitis leads to liver fibrosis and cirrhosis. Cirrhosis is a major cause of worldwide
morbidity and mortality. Macrophages play a key role in fibrosis progression and reversal …

Activating Nrf2 through inhibiting Keap1 has been proven to alleviate oxidative stress and
related diseases, including nonalcoholic fatty liver disease (NAFLD). Traditional Keap1 …

Nonalcoholic fatty liver disease (NAFLD), characterized by ectopic fat accumulation in
hepatocytes, is closely linked to insulin resistance and is the most frequent complication of …